Xilio Therapeutics Inc (NASDAQ: XLO) is 89.09% higher on its value in year-to-date trading and has touched a low of $0.49 and a high of $2.14 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The XLO stock was last observed hovering at around $1.29 in the last trading session, with the day’s loss setting it -0.25%.
Currently trading at $1.04, the stock is 2.38% and 18.52% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.22 million and changing -19.38% at the moment leaves the stock 13.41% off its SMA200. XLO registered -45.55% loss for a year compared to 6-month loss of -17.46%. The firm has a 50-day simple moving average (SMA 50) of $0.87292 and a 200-day simple moving average (SMA200) of $0.91504.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 31.65% gain in the last 1 month and extending the period to 3 months gives it a 19.89%, and is -18.11% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 19.60% over the week and 14.53% over the month.
Xilio Therapeutics Inc (XLO) has around 73 employees, a market worth around $45.71M and $2.36M in sales. Profit margin for the company is -2780.27%. Distance from 52-week low is 112.24% and -51.40% from its 52-week high. The company has generated returns on investments over the last 12 months (-159.90%).
The EPS is expected to grow by 58.75% this year
35.0 institutions hold shares in Xilio Therapeutics Inc (XLO), with institutional investors hold 51.17% of the company’s shares. The shares outstanding are 27.61M, and float is at 21.31M with Short Float at 0.49%. Institutions hold 30.22% of the Float.
The top institutional shareholder in the company is BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC with over 3.79 million shares valued at $3.59 million. The investor’s holdings represent 13.5618 of the XLO Shares outstanding. As of 2024-06-30, the second largest holder is ROCK SPRINGS CAPITAL MANAGEMENT LP with 3.0 million shares valued at $2.85 million to account for 10.7595 of the shares outstanding. The other top investors are RIVERVEST VENTURE MANAGEMENT LLC which holds 1.44 million shares representing 5.1641 and valued at over $1.37 million, while FMR LLC holds 5.0008 of the shares totaling 1.4 million with a market value of $1.32 million.
Xilio Therapeutics Inc (XLO) Insider Activity
The most recent transaction is an insider purchase by GILEAD SCIENCES, INC., the company’s 10% Owner. SEC filings show that GILEAD SCIENCES, INC. bought 485,250 shares of the company’s common stock on Apr 02 ’24 at a price of $0.76 per share for a total of $0.37 million. Following the purchase, the insider now owns 7.35 million shares.
Xilio Therapeutics Inc disclosed in a document filed with the SEC on Feb 08 ’24 that Atlas Venture Fund XI, L.P. (10% Owner) sold a total of 733 shares of the company’s common stock. The trade occurred on Feb 08 ’24 and was made at $0.64 per share for $469.0. Following the transaction, the insider now directly holds 2.02 million shares of the XLO stock.
Still, SEC filings show that on Feb 08 ’24, Atlas Venture Fund XI, L.P. (10% Owner) disposed off 267 shares at an average price of $0.64 for $171.0. The insider now directly holds 734,546 shares of Xilio Therapeutics Inc (XLO).
